Lumpectomy — How It Works, Benefits & Recovery — Procedure Guide, Recovery & Risks | MyMedicPlus

Lumpectomy — also termed breast-conserving surgery (BCS), wide local excision (WLE), or partial mastectomy — is the surgical removal of a breast tumour along with a rim of surrounding healthy breast tissue (the surgical margin), while preserving the remaining breast. It is the standard surgical treatment for early-stage invasive breast cancer and ductal carcinoma in situ (DCIS) in eligible patients, and has replaced mastectomy as the most commonly performed breast cancer surgery in high-income countries. The oncological principle is adequate local disease control: removing the tumour with a clear margin (no tumour cells at the cut edge) eliminates the primary cancer, while adjuvant whole-breast radiotherapy eradicates any residual microscopic disease in the remaining breast tissue, reducing local recurrence to below 1% per year. Multiple landmark randomised trials, including the NSABP B-06 trial (Fisher et al., NEJM 1985) and the Milan I trial, established that lumpectomy with radiotherapy achieves equivalent overall survival to mastectomy in eligible patients with early-stage disease. The choice of lumpectomy over mastectomy preserves breast appearance, sensation, and body image, all of which are significant contributors to quality of life and psychological wellbeing in breast cancer survivors.

Lumpectomy is appropriate for early-stage breast cancer (Stage I and IIA–IIB) where the tumour is small enough relative to breast size to allow excision with adequate margins and acceptable cosmesis. Key eligibility criteria include: unifocal disease (single tumour or a few closely grouped calcifications), tumour-to-breast ratio allowing removal without significant deformity, patient ability and willingness to receive post-operative radiotherapy, and absence of absolute contraindications. Contraindications to lumpectomy include multicentric disease (multiple tumours in different breast quadrants), prior radiotherapy to the chest wall or breast (limits ability to give adjuvant radiotherapy), pregnancy where radiotherapy cannot be deferred safely, inflammatory breast cancer, and inability to achieve clear surgical margins after two re-excision attempts. Relative contraindications include very large tumour-to-breast ratio, extensive lymphovascular invasion, and certain connective tissue diseases (scleroderma, active lupus) that increase radiation sensitivity. Neoadjuvant chemotherapy given before surgery to shrink a larger primary tumour (tumour downstaging) converts patients with borderline tumour-to-breast ratios from mastectomy-only candidates to lumpectomy-eligible — a principal rationale for neoadjuvant systemic therapy in breast cancer management.

Pre-operatively, the radiologist places a localisation device — a wire hooked at the tumour, or a radioactive or magnetic seed — to guide the surgeon to the often non-palpable tumour. On the day of surgery, a lymphoscintigraphy injection (technetium-labelled nanocolloid) is given around the nipple or tumour for sentinel lymph node biopsy (SLNB). Under general or local anaesthesia, the surgeon makes an incision over or adjacent to the tumour — curved along natural skin tension lines to minimise scar visibility — and excises the tumour with the target rim of surrounding healthy tissue using electrocautery. The specimen is orientated (surgical clips on multiple margins) for the pathologist to map the three-dimensional margin status. Concurrently or through a separate small axillary incision, the sentinel lymph nodes (the first nodes draining the breast) identified by isotope and/or blue dye mapping are excised. If sentinel nodes contain tumour on intraoperative assessment, complete axillary clearance may be performed. The tumour cavity is marked with surgical clips for radiation planning. The incision is closed in layers and the wound dressed.

The procedure is performed in an appropriately equipped facility by experienced specialist clinicians. Prior to commencement, the patient undergoes pre-procedural assessment including vital signs measurement, review of relevant investigations, and confirmation of informed consent. Intravenous access is established and monitoring equipment including ECG, pulse oximetry, and blood pressure monitoring is applied.

The procedural site is prepared according to aseptic technique standards. Anaesthesia or analgesia is administered as appropriate for the specific procedure and patient needs, ranging from local anaesthesia for minor procedures to regional or general anaesthesia for more complex interventions.

The procedure is performed under direct visualisation or image guidance as appropriate. Key technical steps are executed with attention to anatomical landmarks and patient safety parameters. Haemostasis is achieved and confirmed before completion. Post-procedural assessment includes clinical evaluation of the immediate result, complication surveillance, and documentation of the procedure.

Recovery room monitoring continues until the patient meets defined discharge criteria. Written post-procedural instructions covering activity restrictions, wound care, medication management, and symptoms requiring urgent review are provided before discharge.

The primary benefit of lumpectomy is the preservation of the breast with equivalent long-term survival to mastectomy, as established in multiple prospective randomised trials including NSABP B-06, the Milan series, and the EORTC 10801 trial. The 20-year overall survival for early breast cancer treated with lumpectomy plus radiotherapy is equivalent to that with mastectomy in appropriately selected patients, meaning patients lose no survival advantage by choosing breast conservation. Preservation of the breast has significant psychological benefits: body image, sexual self-confidence, and post-treatment quality of life scores are consistently higher in women who undergo lumpectomy compared with those who receive mastectomy and reconstruction, as shown in the EORTC QL trial and other quality-of-life studies. Recovery from lumpectomy is substantially faster and simpler than from mastectomy: most patients are discharged the same day or after one overnight stay, return to normal activities within 2–3 weeks, and avoid the prolonged recovery from major reconstruction. The procedure is oncologically sound — achieving equivalent distant metastasis-free survival — confirming that local surgical treatment does not influence systemic disease control in early breast cancer.

Positive surgical margins — tumour cells present at the cut edge of the specimen — occur in 20–25% of initial lumpectomy procedures and require re-excision to achieve clear margins. Multiple re-excisions to achieve clearance may ultimately require conversion to mastectomy in 5–10% of eligible patients. Seroma (fluid collection in the surgical cavity) occurs in 10–20% and may require aspiration in the outpatient clinic if large or symptomatic. Haematoma (blood collection) is managed conservatively unless rapidly expanding, which requires surgical evacuation. Wound infection affects 2–5% and responds to oral antibiotics. Sensory changes including numbness, tingling, and altered sensation over the breast and upper arm occur in 10–30% from nerve disruption during axillary sentinel node surgery — most resolve over 6–18 months. Arm lymphoedema risk after sentinel lymph node biopsy alone is less than 5%, much lower than after full axillary dissection (20–25%). Cosmetic changes from tissue removal — breast asymmetry, contour deformity, skin tethering — affect 10–30% and can be addressed with immediate or delayed oncoplastic reconstruction techniques. Local recurrence with appropriate radiotherapy is approximately 0.5–1% per year, with a 10-year cumulative local recurrence rate of 5–10%.

Most patients are discharged the same day as surgery. A surgical bra or sports bra provides support and comfort in the first 1–2 weeks. A drain is occasionally placed in the axilla after sentinel node surgery and removed before discharge or at 2–5 days when drainage reduces below 30 ml per day. Pain is managed with regular paracetamol and ibuprofen; strong opioids are rarely required. Bruising and swelling at the operation site resolve over 2–4 weeks. Arm exercises on the operated side — guided by a physiotherapist — are started within 24 hours of surgery to maintain shoulder range of motion and reduce lymphoedema risk. Restrictions include no lifting above 5 kg for 2 weeks and avoidance of swimming until wound fully healed (typically 3–4 weeks). Driving resumes when the patient can perform an emergency stop comfortably. Return to desk work is typically 1–2 weeks; physical or manual work at 3–4 weeks. Adjuvant radiotherapy (whole-breast irradiation) begins 4–6 weeks after surgery once the wound is healed; modern hypofractionated schedules of 15–16 daily fractions over 3 weeks have replaced the previous 25-fraction 5-week schedule with equivalent oncological efficacy and comparable side effects. Systemic adjuvant treatment — endocrine therapy (tamoxifen or aromatase inhibitor) for hormone receptor-positive cancers, chemotherapy for high-risk cases, or anti-HER2 therapy — is planned by the multidisciplinary oncology team.